Back to Lung Cancer
This trial is complete. It is no longer accepting participants. Results may be available on ClinicalTrials.gov.

NCT03673657

NCT03673657
Completed Phase 2

Who may be able to join

Who might be able to join this trial:

  • You have been diagnosed with non-small cell lung cancer at an advanced stage (stage 3A, 3B, or 3C) that cannot be removed by surgery
  • You have received a specific combination of chemotherapy and radiation therapy given at the same time as the main treatment
  • Your nutritional status before treatment was assessed as either "well-nourished" or "mildly malnourished" using a specific scoring tool called the PG-SGA (confirm with trial site)
  • You are generally able to carry out daily activities with little or no limitation, as measured by a standard medical scale (ECOG score of 0 or 1)
  • Your doctors estimate you are likely to live for at least 6 months
  • You are able to safely receive chemotherapy and radiation therapy without medical reasons preventing it

Who may not be able to join:

  • You have serious problems with how your gut or intestines work, or your body cannot tolerate being fed through the digestive system
  • You are experiencing severe vomiting, bleeding in your digestive system, or a blockage in your intestines
  • You are severely malnourished, or your body cannot tolerate receiving chemotherapy and radiation therapy together

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

Phase 2: approximately ~30% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.

Trial details

Status
Completed
Phase
Phase 2
Sponsor
Sun Yat-sen University
Registry
clinicaltrials_gov
Start date
10 August 2018
Est. completion
16 March 2020

Where this trial is recruiting

🇨🇳 China

Primary endpoints

The incidence of weight loss ≥5% during the treatment

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 30 June 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

View original record on ClinicalTrials.gov